An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients with Early Breast Cancer Treated with Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)
- Conditions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 156
- Registration Number
- NCT06690489
- Locations
- 🇬🇷
Syrgos Hospital, Athenes, Greece
🇫🇷Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
🇮🇹Sant'Orsola-Malpighi Hospital - University of Bologna, Bologne, Italy
The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study.
- Conditions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 245
- Registration Number
- NCT06688370
- Locations
- 🇫🇷
Cen Experimental, Dijon, France
FIH Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors with MET Alterations
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 140
- Registration Number
- NCT06669117
- Locations
- 🇺🇸
Gabrail Cancer Research Center, Canton, Ohio, United States
🇺🇸Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
Study on Structum® in Adult Patients with Osteoarthritis (TRUST)
- Conditions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 150
- Registration Number
- NCT06623773
- Locations
- 🇵🇱
Maciej Dołżyński, Bialystok, Poland
🇵🇱Piotr Ligocki, Bydgoszcz, Poland
🇵🇱Elżbieta Pietrus- Dunaszewska, Katowice, Poland
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 171
- Registration Number
- NCT06567015
- Locations
- 🇪🇸
Vall d'Hebron Institut d'Oncologia, Barcelona, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇺🇸Oncology Consultants (OC) - Texas Medical Center - Cancer Center, Houston, Texas, United States
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 368
- Registration Number
- NCT06500494
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
- Conditions
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 37
- Registration Number
- NCT05810740
- Locations
- 🇫🇷
Biotrial, Rennes, France
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
- Conditions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 130
- Registration Number
- NCT05599334
- Locations
- 🇧🇪
Clinique Saint-Luc Bouge, Bouge, Belgium
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
- Conditions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 200
- Registration Number
- NCT05546905
- Locations
- 🇫🇷
CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Lyon, Rhône Alpes, France
Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Pierre Fabre Medicament
- Registration Number
- NCT05545215